Experimental Validation Programme
Build evidence before application-specific translation.
Aurealix is preparing two independent initial validation pathways. Neither depends on the other to establish experimental value.
Track A — Adaptive Bioelectronics
Peripheral bioelectronic interaction.
The initial programme is intended to investigate controlled bioelectronic interaction through functional observation, mapping, prospective prediction and increasingly selective intervention.
Potential later translation pathways include assistive neurotechnology, neuroprosthetic interfaces, selective peripheral neuromodulation and bioelectronic approaches to pain modulation.
Track B — Probabilistic Intervention & Proteostasis
Longitudinal biological-state research.
The programme is intended to investigate bounded probabilistic intervention alongside changing biological states and recovery dynamics under controlled and reproducible conditions.
Disease- or model-specific translation will follow only where experimental evidence justifies progression.
Validation progression
Experimental first. Clinical later.
Research architecture → experimental validation → application validation → clinical translation.
The purpose of the initial programme is not to claim clinical efficacy. It is to establish reproducible evidence for underlying technical and biological principles before application-specific or clinical studies are considered.
Future convergence
Complementary evidence may create new questions.
If both tracks develop independent experimental support, later research may investigate whether adaptive bioelectronic interaction and changing biological state can inform one another.
This is a future research direction rather than a current validation dependency.
Collaboration